Rubraca and Presyncope - a phase IV clinical study of FDA data

Summary:

Presyncope is reported as a side effect among people who take Rubraca (rucaparib camsylate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Vitamin D3, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Presyncope when taking Rubraca. It is created by eHealthMe based on reports of 10,770 people who have side effects when taking Rubraca from the FDA, and is updated regularly.

What is Rubraca?

Rubraca has active ingredients of rucaparib camsylate. eHealthMe is studying from 10,770 Rubraca users. Check the latest studies of Rubraca.

What is Presyncope?

Presyncope is found to be associated with 1,366 drugs and 1,286 conditions by eHealthMe. Check the latest studies of Presyncope.

On Jul, 16, 2026

10,770 people reported to have side effects when taking Rubraca.
Among them, 21 people (0.19%) have Presyncope.

Among these 21 people:

How long have people been on Rubraca when they have Presyncope? *

What is the gender of people who have Presyncope when taking Rubraca? *

female: 95 %
male: 5 %

What is the age of people who have Presyncope when taking Rubraca? *

What are other drugs people take besides Rubraca? *

What are other side effects people have besides Presyncope? *

Fatigue (feeling of tiredness): 14 people, 66.67%
Weakness: 11 people, 52.38%
Nausea (feeling of having an urge to vomit): 11 people, 52.38%
Dyspnea (difficult or laboured breathing): 8 people, 38.10%
Depression: 6 people, 28.57%
Constipation: 5 people, 23.81%
Dry Skin: 5 people, 23.81%
Abdominal Distension: 4 people, 19.05%
Joint Pain: 4 people, 19.05%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 19.05%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 15 people, 71.43%
Malignant Neoplasm Of Uterine Adnexa (cancer tumour of uterus surrounding ,ovaries ,fallopian tubes ,ligaments): 3 people, 14.29%
Carbohydrate Antigen 125 Increased: 3 people, 14.29%
Retroperitoneal Cancer (cancer between the peritoneum and the posterior abdominal wall): 1 person, 4.76%
Prostate Cancer: 1 person, 4.76%
Metastasis (spreadable cancer to other organ from origin): 1 person, 4.76%
Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 1 person, 4.76%
High Blood Pressure: 1 person, 4.76%
Disease Recurrence: 1 person, 4.76%
Breast Cancer Female: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Rubraca and have Presyncope?

- Check whether Presyncope is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rubraca:

Rubraca (10,770 reports)

Presyncope treatments and more:

Presyncope (26,156 reports)

Browse all side effects of Rubraca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Presyncope:

Presyncope (1,366 drugs)

Browse all the conditions that are associated with Presyncope:

Presyncope (1,286 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rucaparib camsylate (the active ingredients of Rubraca) and Rubraca (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.